Evaluating B001 Injection for Neuromyelitis Optic Spectrum Disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase Ib clinical trial aims to assess the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of B001 injection in patients with aquaporin-4 antibody positive neuromyelitis optic spectrum disorder (NMOSD). Participants will receive either the B001 injection or a placebo, and their responses will be monitored over the course of the study. The trial focuses on individuals who have experienced at least one relapse in the past year and have specific disability scores. The goal is to determine how well B001 can manage symptoms and improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. NMOSD as defined by either of the following 2015 criteria with anti-AQP4 antibody (Ab) seropositive status at screening
2. Clinical evidence of at least 1 documented relapse in last 12 months prior to screening
3. Expanded Disability Status Scale (EDSS) score from 0 to 7.5 inclusive at screening
4. Age 18 to 70 years, inclusive at the time of informed consent

Exclusion Criteria:

1. Any previous treatment with anti-CD20, eculizumab, anti-BLyS monoclonal antibody (e.g., belimumab), any other treatment for prevention of multiple sclerosis (MS) relapse (e.g., interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate) within 6 months prior to baseline.
2. Received immunosuppression such as azathioprine, mycophenolate mofetil, methotrexate, cyclophosphamide, tacrolimus, mitoxantrone, cyclosporine A, etc, and rug therapy, biological agents such as satralizumab, tocilizumab, eculizumab, etc, 3 months prior to the first administration.
3. Evidence of serious uncontrolled concomitant diseases that may preclude participant participation, as described; Other nervous system disease, cardiovascular disease, hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal/urologic disease, digestive system disease, congenital or acquired severe immunodeficiency.
4. Known active infection within 3 months prior to baseline
5. Pregnancy or lactation.
6. History of severe allergic reaction to a biologic agent
7. Evidence of chronic active hepatitis B or C
8. Evidence of active tuberculosis
9. Following laboratory abnormalities at screening\*:

   1. White blood cells (WBC) \<4.0 x10\^3/microliter (μL)
   2. Absolute neutrophil count (ANC)
   3. Absolute lymphocyte count \<0.5 x10\^3/μL
   4. Platelet count \<80 x 10\^9/ L
   5. Aspartate aminotransferase (AST) or alanine aminotransferase
10. History of drug or alcohol abuse within 6 months prior to baseline
11. Receipt of any live or live attenuated vaccine within 4 weeks prior to baseline
12. Uncontrolled systemic diseases, including hypertension that cannot be effectively controlled after treatment (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg), diabetes, gastrointestinal diseases, etc.; or the investigator believes that there is anything inappropriate reasons for selection.

Where it's running

• Beijing Tiantan Hospital Capital Medical University
  Beijing, Beijing Municipality, China Recruiting
• First Hospital of Shanxi Medical University
  Taiyuan, Shanxi, China Recruiting
• Tangdu hospital,fourth military medical university
  Xi’an, Shanxi, China Recruiting
• Tianjin Medical University General Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Fu-Dong Shi, MD,PhD — Tianjin Medical University General Hospital
• Study coordinator: Fu-Dong Shi, MD,PhD
• Email: Shifudong219@163.com
• Phone: 022-60814587

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Noninvasive transcranial temporal interference stimulation for neuropathic pain in NMOSD

  Researchers will try noninvasive transcranial temporal interference stimulation to reduce chronic neuropathic pain in adults with neuromyelitis optica spectrum disorder (NMOSD).

  Recruiting Tang-Du Hospital · Xi'an, Shaanxi · NCT07377305

• BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases

  This trial will try personalized BAFF‑R CAR T cells to reduce disease activity in people with hard‑to‑treat conditions such as CIDP, NMOSD, myasthenia gravis, and inflammatory myopathies.

  Recruiting Phase 1/2 Tianjin Medical University General Hospital · Tianjin, Tianjin Municipality · NCT07022197

• Monoclonal antibody treatments for AQP4-positive neuromyelitis optica spectrum disorder

  This registry will compare different monoclonal antibody therapies to see if they are safe and help adults in China who have AQP4-positive NMOSD.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06885957

• AI-assisted care for Multiple Sclerosis

  This study is testing whether using AI can help doctors better diagnose and treat people with Multiple Sclerosis by analyzing real-world data.

  Recruiting at 3 sites icometrix · Prague, Praha 2 and 2 other locations · NCT06280755

• Collecting blood samples from patients undergoing plasma exchange

  This study is collecting blood samples from patients with immune-related diseases who are having plasma exchange to see how their antibody levels change during treatment and to use the samples for future research.

  Recruiting University of Iowa · Iowa City, Iowa · NCT05004493

• Observational study of neuroinflammation diseases in China

  This study is trying to see how brain and spinal cord changes in people with neuroinflammatory diseases can help us understand their condition better over a year of MRI scans.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT04106830

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.